US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Avacta Group Plc

0.8600

0.0000

Volume:- -

Turnover:- -

Market Cap:372.75M

PE:-4.48

High:0.8600

Open:0.8600

Low:0.8600

Close:0.8600

52wk High:1.11

52wk Low:0.4011

Shares:433.44M

Float Shares:386.51M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.1920

EPS(LYR):-0.1920

ROE:-167.95%

ROA:-32.63%

PB:1893.48

PE(LYR):-4.48

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Avacta Group Plc

Exchange:

PINK LIMITED

Establishment Date:

2003

Employees:

151

Office Location:

Scale Space White City Imperial College Campus,58 Wood Lane,London,Greater London,United Kingdom

Website:

https://avacta.com/

Zip Code:

W12 7RZ

Phone:

Fax:

- -

Introduction:

Avacta Group Plc develops cancer therapies and diagnostics in the United Kingdom, France, North America, South Korea, and rest of Asia and Europe. The company operates through Diagnostics and Therapeutics segments. It develops products based on its proprietary Affimer and pre|CISION technology platforms. The company develops AVA6000, FAPa-activated doxorubicin that is in Phase I clinical trial for treating locally advanced or metastatic-selected solid tumors; AVA3996, a tumor-targeted proteasome inhibitor based on bortezomib; AVA-028-PD-L1 Affimer/ImmunoCytokines; AVA-021 - PD-L1 Affimer/LAG-3 Affimer; and TMAC platform that utilizes the proprietary pre|CISION substrate to provide for the selective release of a drug moiety by FAPa. The company has a collaboration agreement with LG Chem for developing and commercializing LR19128 PD-L1 XT; and collaboration and license agreement with Avacta and Daewoong Pharmaceutical Co. Ltd. for developing AFX-001 for solid organ transplant and graft vs host Disease, and AFX-002 for multiple sclerosis. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/AVCTF/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AVCTF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVCTF\",,,,,undefined,":{"symbol":"AVCTF","market":"US","secType":"STK","nameCN":"Avacta Group Plc","latestPrice":0.86,"timestamp":1770757200000,"preClose":0.86,"halted":0,"volume":0,"delay":15,"changeRate":0,"floatShares":386513762,"shares":433435252,"eps":-0.191983,"marketStatus":"Not Yet Opened","change":0,"latestTime":"02-10 16:00:00 EST Delay","open":0.86,"high":0.86,"low":0.86,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.191983,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770800400000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"PINK LIMITED","adjPreClose":0.86,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVCTF\",,,,,undefined,":{"symbol":"AVCTF","floatShares":386513762,"roa":"-32.63%","roe":"-167.95%","lyrEps":-0.191983,"shares":433435252,"dividePrice":0,"high":0.86,"amplitude":0,"preClose":0.86,"low":0.86,"week52Low":0.4011,"pbRate":"1893.48","psRate":"2412.93","week52High":1.11,"institutionHeld":0,"latestPrice":0.86,"eps":-0.191983,"divideRate":0,"volume":0,"delay":15,"ttmEps":-0.191983,"open":0.86,"prevYearClose":0.77795,"prevWeekClose":0.86,"prevMonthClose":0.7384,"prevQuarterClose":0.778,"fiveDayClose":0.7736,"twentyDayClose":0.778,"sixtyDayClose":1.05},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AVCTF\",params:#limit:5,,,undefined,":[{"date":"2024-04-30","symbol":"AVCTF","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1714464000000,"name":null,"time":"","dateTimestamp":1714449600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AVCTF\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AVCTF\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6667,"buy":0,"hold":0.3333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0,"analysts":3,"updateTime":1749445200000},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":23568713,"yearFounded":2003,"employeeNum":151,"address":"Scale Space White City Imperial College Campus,58 Wood Lane,London,Greater London,United Kingdom","zipCode":"W12 7RZ","officePhone":"44 203 9110353"},"stockCompanyDetail":{"websiteUrl":"https://avacta.com/","description":"Avacta Group Plc develops cancer therapies and diagnostics in the United Kingdom, France, North America, South Korea, and rest of Asia and Europe. The company operates through Diagnostics and Therapeutics segments. It develops products based on its proprietary Affimer and pre|CISION technology platforms. The company develops AVA6000, FAPa-activated doxorubicin that is in Phase I clinical trial for treating locally advanced or metastatic-selected solid tumors; AVA3996, a tumor-targeted proteasome inhibitor based on bortezomib; AVA-028-PD-L1 Affimer/ImmunoCytokines; AVA-021 - PD-L1 Affimer/LAG-3 Affimer; and TMAC platform that utilizes the proprietary pre|CISION substrate to provide for the selective release of a drug moiety by FAPa. The company has a collaboration agreement with LG Chem for developing and commercializing LR19128 PD-L1 XT; and collaboration and license agreement with Avacta and Daewoong Pharmaceutical Co. Ltd. for developing AFX-001 for solid organ transplant and graft vs host Disease, and AFX-002 for multiple sclerosis. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.","exchange":"PINK LIMITED","name":"Avacta Group Plc","nameEN":"Avacta Group Plc"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"AVCTF\",market:\"US\",,,undefined,":null}}